Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cannabinoids as Glial Cell Modulators in Ischemic Stroke: Implications for Neuroprotection

  • Vicente-Acosta, Andrés
  • Ceprian, Maria
  • Sobrino, Pilar
  • Pazos, Maria Ruth
  • Loría, Frida
Stroke is the second leading cause of death worldwide following coronary heart disease. Despite significant efforts to find effective treatments to reduce neurological damage, many patients suffer from sequelae that impair their quality of life. For this reason, the search for new therapeutic options for the treatment of these patients is a priority. Glial cells, including microglia, astrocytes and oligodendrocytes, participate in crucial processes that allow the correct functioning of the neural tissue, being actively involved in the pathophysiological mechanisms of ischemic stroke. Although the exact mechanisms by which glial cells contribute in the pathophysiological context of stroke are not yet completely understood, they have emerged as potentially therapeutic targets to improve brain recovery. The endocannabinoid system has interesting immunomodulatory and protective effects in glial cells, and the pharmacological modulation of this signaling pathway has revealed potential neuroprotective effects in different neurological diseases. Therefore, here we recapitulate current findings on the potential promising contribution of the endocannabinoid system pharmacological manipulation in glial cells for the treatment of ischemic stroke., This work was supported by research grants from Hospital Universitario Fundación Alcorcón (HUFA-15044) to PS and Instituto de Salud Carlos III (PI20/00934, co-funded by Fondo Europeo de Desarollo Regional, FEDER) to FL. AV-A is supported by a contract from Comunidad Autónoma de Madrid (NEUROMETAB-CM, B2017/BMD-3700). The funders had no role in designing or conducting the study.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Glial cell activation precedes neurodegeneration in the cerebellar cortex of the YG8–800 murine model of Friedreich ataxia

  • Vicente-Acosta, Andrés
  • Herranz-Martín, Saúl
  • Pazos, Maria Ruth
  • Galán-Cruz, Jorge
  • Amores, Mario
  • Loria, Frida
  • Díaz-Nido, Javier
Friedreich ataxia is a hereditary neurodegenerative disorder resulting from reduced levels of the protein frataxin due to an expanded GAA repeat in the FXN gene. This deficiency causes progressive degeneration of specific neuronal populations in the cerebellum and the consequent loss of movement coordination and equilibrium, which are some of the main symptoms observed in affected individuals. Like in other neurodegenerative diseases, previous studies suggest that glial cells could be involved in the neurodegenerative process and disease progression in patients with Friedreich ataxia. In this work, we followed and characterized the progression of changes in the cerebellar cortex in the latest version of Friedreich ataxia humanized mouse model, YG8–800 (Fxn:YG8s(GAA)), which carries a human FXN transgene containing >800 GAA repeats. Comparative analyses of behavioral, histopathological, and biochemical parameters were conducted between the control strain Y47R and YG8–800 mice at different time points. Our findings revealed that YG8–800 mice exhibit an ataxic phenotype characterized by poor motor coordination, decreased body weight, cerebellar atrophy, neuronal loss, and changes in synaptic proteins. Additionally, early activation of glial cells, predominantly astrocytes and microglia, was observed preceding neuronal degeneration, as was increased expression of key proinflammatory cytokines and downregulation of neurotrophic factors. Together, our results show that the YG8–800 mouse model exhibits a stronger phenotype than previous experimental murine models, reliably recapitulating some of the features observed in humans. Accordingly, this humanized model could represent a valuable tool for studying Friedreich ataxia molecular disease mechanisms and for preclinical evaluation of possible therapies., This study was supported by research grants from the Ministerio de Ciencia e Innovacion, Spain (MICINN, grant PID2019-111338RB-I00, Pr. Javier Díaz-Nido), Instituto de Salud Carlos III, Spain (PI20/00934, co-funded by Fondo Europeo de Desarrollo Regional, FEDER. Dr. Frida Loria) and Association Française de l’Ataxie de Friedreich (AFAF, Dr. Frida Loria), and Ataxia UK small grant (Dr. Saúl Herranz-Martín). Dr.Andres Vicente-Acosta was supported by a contract from Comunidad Autónoma de Madrid (NEUROMETAB-CM, B2017/BMD-3700) and by PI20/00934. Dr. Saúl Herranz-Martín was partially supported by the program Atraccion´ de Talento Investigador (2017-T2/BMD-5323)